Molecular Intelligence^™ for Other Solid Tumors

Caris Life Sciences provides broad tumor profiling and biomarker analysis for therapeutic associations for all solid tumors. The Comprehensive profile reports both On- and Off-Compendium therapeutic associations. The Comprehensive profile also includes the Clinical Trials Connector^™ that matches open, relevant clinical trials based each patient’s unique biomarker profile.

For New York state physicians, a separate profile menu is available.

Agent(s) /Biomarker Status Reported	Biomarker	Platform
Comprehensive
docetaxel, paclitaxel	TLE3	IHC
	TUBB3	IHC
	Pgp	IHC
capecitabine, fluorouracil, pemetrexed	TS	IHC
doxorubicin, liposomal-doxorubicin, epirubicin	HER2	FISH/CISH
	TOP2A	IHC
	Pgp	IHC
irinotecan, topotecan	TOPO1	IHC
gemcitabine	RRM1	IHC
temozolomide, dacarbazine	MGMT	IHC (excluding glioma)
	MGMT-Me	Pyrosequencing (glioma ONLY)
	IDH1*	Next-Gen. Sequencing
nab-paclitaxel	SPARCm	IHC
	SPARCp	IHC
abiraterone, bicalutamide, flutamide	AR	IHC
fulvestrant, tamoxifen, toremifene, anastrozole, exemestane, letrozole, megestrol acetate, leuprolide, goserelin	ER	IHC
	PR	IHC
trastuzumab, lapatinib	HER2	IHC, FISH/CISH
imatinib	cKIT	Next-Gen. Sequencing
	PDGFRA	Next-Gen. Sequencing
sunitinib, sorafenib (GIST only)	cKIT	Next-Gen. Sequencing
vemurafenib	BRAF	Next-Gen. Sequencing
everolimus, temsirolimus, clinical trials	PIK3CA	Next-Gen. Sequencing
	PTEN	IHC
clinical trials (cMET inhibitors)	cMET	IHC
clinical trials (MEK and BRAF inhibitors)	BRAF	Next-Gen. Sequencing
	KRAS	Next-Gen. Sequencing
	NRAS	Next-Gen. Sequencing
clinical trials (angiogenesis inhibitors)	VHL	Next-Gen. Sequencing
clinical trials (PIK3CA, mTOR, MEK, angiogenesis, and IGF pathway inhibitors)	PTEN	Next-Gen. Sequencing